Enzyme-Linked Bridging Assay Method for the Quantification of Oligonucleotide-Based Drugs in Biological Matrices

Jie Fu,Yunjuan Sun,Shaoyou Xia,Lihou Dong,Qingqing Wang,Lun Ou,Xianfei Shen,Zhiguo Lv,Haifeng Song
DOI: https://doi.org/10.1089/nat.2011.0319
2011-01-01
Nucleic Acid Therapeutics
Abstract:With ongoing efforts to develop oligonucleotide-based (ODN-based) therapeutics, there is a need for a sensitive, high-throughput method of quantification of ODN-based drugs in biological matrices. To overcome the insufficient sensitivity and time-consuming sample extraction procedures involved in conventional capillary gel electrophoresis (CGE) and high-performance liquid chromatography (HPLC), we developed a nucleic acid hybridization-based enzyme-linked bridging assay (ELBA), which shows significant advantages over CGE methods in evaluating ODN-based drugs in plasma and tissue: (1) It has higher sensitivity; (2) it involves easier sample extraction procedures; (3) it is suitable for many ODN-based drugs, even those with different secondary structures and modifications, including phosphorothioate oligonucleotide (PSODN), mixed backbones with 2'-O-Me (MBO), locked nucleic acid (LNA) modifications, and B-and C-type CpG sequences; and (4) it is highly selective, even during simultaneous quantification, with regard to intact ODNs and their 3'-metabolites. This universal design produces a rapid, sensitive, specific assay with minimal method development time. It is well suited to high-throughput analysis of various ODN-based drugs.
What problem does this paper attempt to address?